FCGR3A and autoimmune thrombocytopenic purpura: The FcγRIIIa involvement was clearly shown in humans for the first time in 1986 with the anti-FcγRIIIa 3G8 mAb, which raised the platelet level in 50% of immune thrombocytopenic purpura patients refractory to other treatments (16, 17); however, the 3G8 mAb was found to be toxic.